1-5 of 5
Motohisa Takai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Free
Meghan Thompson, Constantine Tam, Kenneth Wu, Sheel Patel, Motohisa Takai, Patrick Phuong, Shelonitda Rose, Mark-David Levin, Talha Munir, Paolo Ghia, John Seymour
Journal: Blood
Blood (2025) 146 (Supplement 1): 5691.
https://doi.org/10.1182/blood-2025-5691
Published: 2025
Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study

Free
Constantine Tam, Chan Cheah, John Seymour, Ricardo Parrondo, Mazyar Shadman, Damien Roos Weil, Stephan Stilgenbauer, Barbara Eichhorst, Herbert Eradat, Steven Treon, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Motohisa Takai, Amit Agarwal, Annamaria Frustaci
Journal: Blood
Blood (2025) 146 (Supplement 1): 3583.
https://doi.org/10.1182/blood-2025-3583
Published: 2025
Journal Articles

CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor

Free
Constantine Tam, John Seymour, Jiayi Shen, Jan Michel, Maryam Sarraf Yazdy, Patrick Brown, Shelonitda Rose, Motohisa Takai, Meghan Thompson, Mark-David Levin, Talha Munir, Paolo Ghia, Jeff Sharman
Journal: Blood
Blood (2025) 146 (Supplement 1): 8245.
https://doi.org/10.1182/blood-2025-8245
Published: 2025
Journal Articles

A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor (BTKi) Zanubrutinib in Patients with Waldenström Macroglobulinemia (WM)

Free
Edwin C. Kingsley, Shannon Fabre, Motohisa Takai, Aileen Cleary Cohen, Jingjing Schneider, Jessica Li, James D'Olimpio
Journal: Blood
Blood (2023) 142 (Supplement 1): 6171.
https://doi.org/10.1182/blood-2023-172881
Published: 2023
Journal Articles

Efficacy and Safety of Zanubrutinib in Japanese Patients with Mature B-Cell Malignancies

Free
Takayuki Ishikawa, Masahiro Takeuchi, Kazuyuki Shimada, Kohmei Kubo, Takeshi Kondo, Katsuya Fujimoto, Tomoaki Fujisaki, Koji Nagafuji, Rika Sakai, Shingo Kurahashi, Tatsuro Jo, Kazutaka Sunami, Senji Kasahara, Tomonori Nakazato, Haiyi Guo, William Novotny, Chris Tankersley, Motohisa Takai, Hui Yao, Jinhua Zhong, Hongjie Zhu, Koji Izutsu
Journal: Blood
Blood (2022) 140 (Supplement 1): 3663–3665.
https://doi.org/10.1182/blood-2022-168696
Published: 2022